Literature DB >> 10320119

Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial.

G Galindo-Rodríguez1, J A Aviña-Zubieta, S Pizarro, V Díaz de León, N Saucedo, M Fuentes, C Lavalle.   

Abstract

OBJECTIVE: To evaluate the efficacy of intravenous cyclophosphamide pulse therapy in patients with optic neuritis associated with systemic lupus erythematosus (SLE). PATIENTS AND METHODS: Ten consecutive patients with optic neuritis due to SLE whose condition was refractory to corticosteroids and oral immunosuppressants were treated with intravenous cyclophosphamide (0.5 to 1.0 g/m2) monthly for 6 months.
RESULTS: All patients had bilateral eye involvement. One eye was legally blind, and 13 eyes could see only hand movements or count fingers. Six patients had evidence of the secondary antiphospholipid antibody syndrome. Complete recovery in visual acuity occurred in 10 eyes (50%), and a partial response occurred in six eyes (30%); four eyes (20%) had no response. Complete response in the field tests occurred in eight eyes (40%), with a partial response in nine eyes (45%); no improvement occurred in three eyes (15%).
CONCLUSIONS: Intravenous cyclophosphamide pulse therapy seems to be an effective treatment for optic neuritis refractory to corticosteroids, oral immunosuppressants, or both. A randomized controlled trial will be necessary to confirm our results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10320119     DOI: 10.1016/s0002-9343(98)00372-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Outcomes of toll-like receptors' antagonism in steroid-resistant optic neuritis; a pilot study.

Authors:  Aditya Sudhalkar; Mayuri Khamar; Bakulesh Khamar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-15       Impact factor: 3.117

2.  Systemic Lupus Erythematosus Presenting as Optic Neuropathy: A Case Report.

Authors:  Salman Zahid; Mustafa Iqbal
Journal:  Cureus       Date:  2019-06-03

3.  Mycobacterium W administration for steroid resistant optic neuritis with long-term follow-up.

Authors:  Aditya Sudhalkar; Mayuri Khamar; Bakulesh Khamar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-09-18       Impact factor: 3.117

Review 4.  Demyelination in rheumatic diseases.

Authors:  A Theodoridou; L Settas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

Review 5.  Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease.

Authors:  T D Myers; J R Smith; M S Wertheim; R A Egan; W T Shults; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

Review 6.  Gender and ocular manifestations of connective tissue diseases and systemic vasculitides.

Authors:  Maria M Choudhary; Rula A Hajj-Ali; Careen Y Lowder
Journal:  J Ophthalmol       Date:  2014-03-17       Impact factor: 1.909

7.  Remedial Effect of Intravenous Cyclophosphamide in Corticosteroid-Refractory Patients in the Acute Phase of Neuromyelitis Optica Spectrum Disorder-Related Optic Neuritis.

Authors:  Ling Wang; Kaiqun Liu; Xiao Tan; Lin Zhou; Yuxin Zhang; Xiaoning Liu; Yue Fu; Wei Qiu; Hui Yang
Journal:  Front Neurol       Date:  2021-01-15       Impact factor: 4.003

8.  Current options for the treatment of optic neuritis.

Authors:  John H Pula; Christopher J Macdonald
Journal:  Clin Ophthalmol       Date:  2012-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.